In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Ascendis Pharma, with a price target of $264.00. The company’s shares opened today at $210.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fye covers the Healthcare sector, focusing on stocks such as Insmed, Ascendis Pharma, and Ionis Pharmaceuticals. According to TipRanks, Fye has an average return of 10.2% and a 56.41% success rate on recommended stocks.
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $251.31, representing a 19.67% upside. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $240.00 price target.
Based on Ascendis Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $158.05 million and a GAAP net loss of $38.86 million. In comparison, last year the company earned a revenue of $36 million and had a GAAP net loss of $109.38 million
Read More on ASND:
Disclaimer & DisclosureReport an Issue
- Ascendis Pharma Submits EMA Application for Achondroplasia Treatment
- Ascendis Pharma submits TransCon CNP marketing authorization application to EMA
- Ascendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
/A%20Lucid%20Motors%20vehicle%20parked%20in%20front%20of%20a%20showroom_%20Image%20by%20Michael%20Berlfein%20via%20Shutterstock_.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
